Financial Performance - The company's operating revenue for 2022 was approximately ¥463.32 million, a decrease of 12.00% compared to ¥526.50 million in 2021[24]. - The net profit attributable to shareholders for 2022 was approximately ¥126.31 million, representing a significant increase of 421.87% from ¥24.20 million in 2021[24]. - Basic earnings per share for 2022 were ¥0.16, an increase of 433.33% from ¥0.03 in 2021[24]. - The total assets at the end of 2022 were approximately ¥1.19 billion, an increase of 16.11% from ¥1.02 billion at the end of 2021[24]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥988.96 million, an increase of 18.95% from ¥831.43 million at the end of 2021[24]. - The company reported a weighted average return on equity of 14.12% for 2022, up from 2.95% in 2021, indicating improved profitability[24]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a 20% year-over-year growth[117]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in Q3 2023, representing a 25% year-over-year growth[118]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[117]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 20% to 1.8 billion RMB[119]. Cash Flow and Investments - The net cash flow from operating activities for 2022 was negative at approximately -¥29.23 million, a decline of 370.08% compared to ¥10.82 million in 2021[24]. - The company faced significant cash flow challenges, with negative cash flow reported in three out of four quarters of 2022[26]. - The company reported a government subsidy of 1,458,129.38 CNY in 2022, down from 2,745,483.97 CNY in 2021, reflecting a decrease in government support[30]. - The company realized an investment income of ¥129.38 million from the sale of equity in Anhui Zhongsheng Suoyuan Biotechnology Co., Ltd., significantly impacting the annual net profit[60]. - Investment income accounted for 97.62% of the total profit, primarily from wealth management product returns and the sale of equity in Anhui Zhongsheng Suoyuan Biotechnology Co., Ltd.[63]. - The net cash flow from investment activities increased by ¥76.91 million compared to the same period last year, mainly due to the redemption of bank wealth management products and term deposits maturing within one year[60]. - The net cash flow from financing activities decreased by ¥5.87 million, a decline of 103.04%, primarily due to rental expenses paid by the subsidiary Golden Designs INC. (N.A.) for warehouse and office space[60]. Market Position and Product Development - The company maintained a strong market position in the health product industry, particularly in the infrared sauna market, despite a significant decline in consumer demand in Europe due to global economic conditions[36]. - The company achieved a revenue increase in the North American market while expanding into new markets such as Australia, compensating for the downturn in Europe[38]. - The company accelerated its R&D efforts, integrating AI voice recognition technology into its infrared sauna products, and was recognized with a gold award at the Anhui Provincial Industrial Design Competition[38]. - The company is developing new air purifier products to meet diverse user needs and enhance market competitiveness[57]. - The company plans to continue expanding its market presence and developing new products, particularly through its subsidiary Golden Designs INC. (N.A.)[66]. - The company is focusing on the long-term development capability in the health industry and will selectively invest in projects with significant growth potential[90]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[117]. - New product launches are expected to contribute an additional 300 million RMB in revenue, with a focus on innovative health technology solutions[117]. - The company aims to launch three new products in the upcoming year, which are anticipated to generate 500 million RMB in sales[144]. Operational Efficiency and Cost Management - The company optimized its supply chain management to control raw material costs, which constitute a significant portion of its operating costs, thereby enhancing market competitiveness[40]. - The company will focus on cost reduction and efficiency improvement to enhance market competitiveness[89]. - The company aims to improve operational efficiency, targeting a 5% reduction in costs through process optimization[117]. - The company has set a target to reduce operational costs by 15% through efficiency improvements[144]. - The gross margin improved to 40%, up from 35% in the previous year, indicating better cost management[119]. - The gross margin improved to 45%, up from 40% in the previous year, reflecting better cost management[144]. Research and Development - The company has a robust R&D system, with 33 new patent applications and international certifications during the reporting period, totaling 304 valid patents and certifications[46]. - Research and development expenses decreased by 18.86% to ¥10,966,626.88, accounting for 2.37% of operating revenue[57]. - The company plans to increase R&D investment to enhance innovation and accelerate new product development[88]. - Investment in R&D increased by 30%, focusing on innovative health technology solutions[144]. - The company is investing 50 million in R&D for new technologies aimed at enhancing product offerings[118]. Governance and Management - The company has established a transparent and effective performance evaluation and incentive mechanism for its management team to enhance motivation and retain talent[101]. - The company adheres to strict information disclosure practices, ensuring timely and accurate communication with investors and stakeholders[102]. - The company has plans for future expansions and strategic initiatives, although specific details were not disclosed in the provided content[108]. - The company has undergone a restructuring of its organizational framework as part of its strategic adjustments[120]. - The company completed the election of the sixth board and supervisory committee, ensuring governance continuity[171]. - The company has maintained the same accounting firm, Zhongzheng Tiantong Accounting Firm, for 4 consecutive years, with an audit fee of 700,000 RMB[149]. Risks and Challenges - The company faces risks from macroeconomic conditions, including potential foreign trade order reductions due to international uncertainties, and plans to adjust product and market structures accordingly[91]. - The company is the leading enterprise in far-infrared sauna products but is affected by price competition from smaller, unregulated manufacturers, prompting a faster pace in new product development and optimization of product structure[91]. - Raw material costs constitute a significant portion of operating costs, and the company will optimize its supply chain and adopt flexible procurement strategies to mitigate risks from price fluctuations[91]. - The company will monitor exchange rate fluctuations closely, as overseas business constitutes a large portion of operations, and will implement strategies to manage foreign exchange risks[92]. Employee and Internal Control - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 3.8868 million CNY[120]. - The company has established a performance-based salary system, combining basic salary and performance bonuses to motivate employees[128]. - The company conducted various training programs to enhance the skills and management levels of its personnel, including management improvement and quality management training[129]. - The internal control system has been strengthened, with a focus on enhancing internal audit supervision and monitoring large fund transactions[132]. - The company has implemented training programs for management and employees to improve compliance awareness and internal control execution[133]. Shareholder Engagement - The company actively engages with investors through various communication channels to enhance transparency and governance[140]. - The company is committed to transparency and shareholder engagement, as evidenced by the detailed reporting of shareholder meeting outcomes and board changes[106]. - The first temporary shareholders' meeting in 2022 had an investor participation rate of 20.93% and approved the proposal to reappoint the accounting firm[106]. - The second temporary shareholders' meeting in 2022 had a participation rate of 21.68% and approved the proposal to transfer equity in a subsidiary[107]. - The third temporary shareholders' meeting in 2022 had a participation rate of 21.78% and approved the election of the sixth board of directors and supervisors[107].

Financial Performance - The company's revenue for Q1 2023 was ¥158,259,198.06, representing a 28.43% increase compared to ¥123,228,041.25 in the same period last year[5] - Net profit attributable to shareholders was ¥11,189,537.80, a significant increase of 116.73% from ¥5,162,844.88 year-on-year[5] - Basic earnings per share rose to ¥0.0139, up 117.19% from ¥0.0064 in the same period last year[5] - The company's net profit for the current period is CNY 18,327,304, representing an increase of 48.3% compared to CNY 12,373,896.73 in the previous period[25] - Operating profit increased to CNY 25,233,202.51, up 31.1% from CNY 19,238,586.03 year-over-year[25] - Total revenue from sales of goods and services reached CNY 149,863,285.01, an increase of 13.9% compared to CNY 131,546,519.87 in the previous period[28] - The total comprehensive income for the current period is CNY 16,808,961.24, compared to CNY 12,208,652.83 in the previous period[26] Cash Flow - The net cash flow from operating activities surged to ¥46,906,552.61, marking a 635.77% increase from ¥6,375,180.75 in the previous year[5] - The net cash flow from operating activities improved significantly to CNY 46,906,552.61, compared to CNY 6,375,180.75 in the previous period[28] - Investment activities generated a net cash flow of CNY 3,368,744.96, a turnaround from a negative cash flow of CNY -13,885,986.01 in the previous period[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,185,304,298.39, a slight decrease of 0.13% from ¥1,186,803,628.67 at the end of the previous year[5] - The company's total assets decreased slightly to CNY 1,185,304,298.39 from CNY 1,186,803,628.67 at the beginning of the year[23] - The total liabilities decreased to CNY 139,722,035.41 from CNY 158,030,326.94, showing a reduction of approximately 11.6%[23] - The total equity attributable to the parent company increased to CNY 998,626,593.49 from CNY 988,955,398.44, reflecting a growth of 1.7%[23] Operating Costs and Expenses - The company reported a 39.72% increase in operating costs, amounting to an increase of ¥31,636,500.00 due to higher sales from its U.S. subsidiary[12] - The total operating costs amounted to CNY 137,305,140.63, up from CNY 105,672,960.28, reflecting a year-over-year increase of 29.9%[24] - Research and development expenses were CNY 2,065,738.44, a decrease of 22.5% from CNY 2,667,178.09 in the previous period[25] Inventory and Accounts Payable - Inventory decreased by ¥45,585,600.00, reflecting a 24.43% decline, mainly due to sales of previously held inventory by the U.S. subsidiary[10] - The company reported a decrease in inventory from CNY 186,574,736.48 to CNY 140,989,089.00, a reduction of approximately 24.4%[22] - The accounts payable decreased from CNY 52,696,877.97 to CNY 40,690,282.01, indicating a decline of about 22.8%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 38,439[17] Foreign Currency and Other Adjustments - The company reported a foreign currency translation difference of CNY -986,922.79, compared to CNY -165,243.90 in the previous period[26]

出席本次业绩说明会的人员有：公司总经理邢芬玲女士、独立董事蒋基路 女士、财务总监张挺峰先生、董事会秘书梁俊女士。 欢迎广大投资者积极参与。 特此公告。 证券代码：300247 证券简称：融捷健康 公告编号：2023－018 融捷健康科技股份有限公司 关于举行 2022 年度报告网上业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记 载、 误导性陈述或重大遗漏。 融捷健康科技股份有限公司（以下简称"公司"）已于 2023 年 04 月 26 日 披露公司《2022 年年度报告》及摘要。为便于广大投资者更深入全面地了解公 司情况，公司将于 2023 年 05 月 11 日（星期四）15:00 至 17:00 在深圳证券 信息有限公司提供的网上平台上举行 2022 年度网上业绩说明会，本次业绩说明 会 将 采 用 网 络 远 程 方 式 召 开 ， 投 资 者 可 登 陆 " 全 景 · 路 演 天 下 " （http://rs.p5w.net）参与本次业绩说明会。 融捷健康科技股份有限公司 董事会 2023 年 04 月 25 日 ...

证券代码：300247 证券简称：桑乐金 编号：2015-003 安徽桑乐金股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 金 星 中信证券股份有限公司 | | | 人员姓名 | 甘 骏 中信证券股份有限公司 | | | | 罗仕嘉 中银基金管理有限公司 | | | | | | | | | 周 密 国投瑞银基金管理有限公司 | | | | 郭 华 光大永明资产管理股份有限公司 | | 时间 | 2015 年 05 月 | 日下午 | | 地点 | | 安徽桑乐金股份有限公司合肥总部三楼接待室 | ...

证券代码：300247 证券简称：桑乐金 编号：2015-005 安徽桑乐金股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 崔 莹 华安基金管理有限公司 | | | 人员姓名 | | | | 时间 | 2015 年 05 月 14 | 日下午 | | 地点 | | 安徽桑乐金股份有限公司合肥总部三楼接待室 | | 上市公司接待人 | | 董事长金道明、董事会秘书胡萍、财务总监汪燕 | | 员姓名 | | | | 投资者关系活动 | 2015 年 05 月 14 | 日下午机构来访人员与公司董事长 ...

Group 1: Company Overview and Market Position - Anhui Sang Le Jin Co., Ltd. is positioned in the health industry, focusing on home health products and services, including air, water, sleep, therapy, and massage-related products [3][4]. - The company aims to evolve from a sauna equipment manufacturer to a comprehensive provider of "home health system solutions" within 3-5 years [4][15]. Group 2: Development Strategy - The company plans to enhance its product structure and diversify its offerings to cover various aspects of family health [3][4]. - Significant investment in research and development is planned to accelerate the company's transformation and upgrade its technology [4][15]. Group 3: Acquisition and Financial Projections - The acquisition of Jiugong Jianye was valued at 81,151 million RMB, with a target of achieving a 20% annual profit growth [5][9]. - Jiugong Jianye's projected net profits for 2015, 2016, and 2017 are set at 5,280 million RMB, 6,610 million RMB, and 7,610 million RMB, respectively [9]. Group 4: Sales and Marketing Strategy - The company has established 22 offices and over 200 distributors domestically, with a focus on expanding its sales channels [8][12]. - Plans include enhancing the domestic marketing network and establishing a direct sales system in the U.S. to capitalize on economic recovery [12][15]. Group 5: Future Outlook - The company anticipates a steady increase in market penetration for health massage products, with a forecasted external sales revenue of 31,677.30 million RMB for 2015 [9][10]. - Internal sales are expected to exceed 1,781.91 million RMB in 2015, reflecting growth potential in the domestic market [10][11].

证券代码：300247 证券简称：乐金健康 安徽乐金健康科技股份有限公司投资者关系活动记录表 编号：2016-001 | --- | --- | --- | --- | |----------------|----------------------------------|--------------------------------------------------|-------------------------------------------------------| | | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | | □ 新闻发布会 | □ 路演活动 | | | | □ 现场参观 | | | | | □ | 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | | | 华泰证券 张立聪； 嘉实基金 谢泽林； 举哲晨资产管理 祁 | | 人员姓名 | | | 莎莎； 中铁宝盈资管 刘嘉杰、沈弘宇；中信证券 孙雯雯； | | | 鹏华基金 金笑非；金控资产 廖刚； | | | | ...

证券代码： 300247 证券简称：乐金健康 编号：2017-001 安徽乐金健康科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 中泰医药：赵磊； 中国健康产业基金：王若麟； | | 人员姓名 | | 浙商财险：章宏帆； 华融渝富：王丹； 和君资本：禚晓龙； | | | | 华泰资管：冯皓琪； 沁元资本：徐梦菲； 中冀投资: 李大 | | | 瑞； | | | | | | | | | 中银国际：高睿婷； 景泰利丰：刘欣； 恒盈资产：杨南翔； | | | | 财通证券：沈瑞； 广发医药 ...

Financial Performance - The company's revenue for Q3 2022 was ¥94,523,466.14, a decrease of 4.88% compared to the same period last year[6]. - Net profit attributable to shareholders was ¥3,713,105.90, down 82.70% year-on-year, while the net profit after deducting non-recurring gains and losses was ¥4,092,591.56, a decrease of 4.57%[6]. - Total revenue for the third quarter of 2022 was CNY 330,663,140.51, a decrease of 10.1% compared to CNY 367,789,975.05 in the same period last year[21]. - The net profit for Q3 2022 was CNY 146,229,493.28, a significant increase from CNY 36,549,298.46 in Q3 2021, representing a growth of 300.5%[22]. - The company reported an operating profit of CNY 154,732,798.88, compared to CNY 42,036,052.00 in the same period last year, marking an increase of 268.5%[22]. - The total comprehensive income for the quarter was CNY 191,420,496.12, compared to CNY 33,487,828.02 in Q3 2021, an increase of 471.5%[23]. - Basic and diluted earnings per share were both CNY 0.1718, up from CNY 0.0376 in the same quarter last year, representing an increase of 356.4%[23]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,200,763,730.47, an increase of 17.47% from the end of the previous year[6]. - Total assets as of September 30, 2022, amounted to CNY 1,200,763,730.47, an increase from CNY 1,022,175,500.47 at the start of the year[19]. - The total liabilities decreased to CNY 148,204,500.59 from CNY 161,064,333.37, reflecting a reduction of 7.9%[19]. - The company’s equity attributable to shareholders increased by 21.51% to ¥1,010,310,330.80 compared to the previous year[6]. Cash Flow - Cash flow from operating activities showed a net outflow of ¥54,436,363.18, representing an increase of 826.89% compared to the previous period[12]. - The cash flow from operating activities was negative at CNY -54,436,363.18, worsening from CNY -5,873,002.92 in the previous year[24]. - The company experienced a net cash outflow from investing activities of CNY -13,875,248.94, an improvement from CNY -67,490,037.99 in the previous year[25]. Inventory and Expenses - The company’s inventory increased by 40.49% to ¥209,557,516.71, attributed to product purchases by its U.S. subsidiary[9]. - Inventory increased to CNY 209,557,516.71 from CNY 149,163,353.47, marking a rise of 40.5%[18]. - Research and development expenses for the quarter were CNY 7,904,373.99, down from CNY 9,969,905.85, reflecting a decrease of 20.7%[22]. - The company’s financial expenses decreased significantly by 1242.54% to -¥11,406,672.37 due to currency exchange rate fluctuations[11]. Shareholder Information - The number of common shareholders at the end of the reporting period was 38,590, with the largest shareholder holding 14.54% of the shares[14]. - The company has a total of 116,912,302 unrestricted shares held by its largest shareholder, accounting for 14.54% of total shares[15]. Investment Income - The company reported a significant increase in investment income of ¥132,698,822.50, up 1393.25% due to the sale of equity in Zhongsheng Suyuan[11]. Deferred Income - The company’s deferred income decreased by 92.80% to ¥9,447.96 as a result of revenue recognition during the reporting period[10].

Financial Performance - The company's revenue for Q3 2022 was ¥94,523,466.14, a decrease of 4.88% compared to the same period last year[6]. - Net profit attributable to shareholders decreased by 82.70% to ¥3,713,105.90, while the net profit excluding non-recurring items was ¥4,092,591.56, down 4.57%[6]. - The company reported a net loss of ¥1,214,805,714.07 as of September 30, 2022, compared to a loss of ¥1,352,972,886.63 at the beginning of the year, indicating an improvement in financial performance[19]. - Total operating revenue for the current period is $330.66 million, down from $367.79 million in the previous period, representing a decrease of approximately 10.1%[21]. - Operating profit increased significantly to $154.73 million from $42.04 million, marking an increase of approximately 268.5%[22]. - Net profit for the current period reached $146.23 million, compared to $36.55 million in the previous period, reflecting an increase of about 300.5%[22]. - Basic and diluted earnings per share improved to $0.1718 from $0.0376, an increase of approximately 356.4%[23]. - The total comprehensive income for the current period was $191.42 million, up from $33.49 million, an increase of approximately 471.5%[23]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,200,763,730.47, representing a 17.47% increase from the previous year[6]. - The total liabilities decreased from ¥161,064,333.37 to ¥148,204,500.59, a reduction of approximately 7.9%[19]. - The total assets increased from ¥1,022,175,500.47 to ¥1,200,763,730.47, reflecting a growth of about 17.5%[19]. - Total current assets increased from ¥501,441,905.33 at the beginning of the year to ¥776,545,111.36, representing a growth of about 54.7%[18]. Cash Flow - Cash flow from operating activities showed a net outflow of ¥54,436,363.18, a 826.89% increase in outflow compared to the previous period[12]. - Cash flow from operating activities showed a net outflow of $54.44 million, worsening from a net outflow of $5.87 million in the previous period[24]. - Cash flow from investing activities resulted in a net outflow of $13.88 million, compared to a net outflow of $67.49 million previously, indicating an improvement[25]. - The company's cash and cash equivalents decreased by 76.26% to ¥21,678,949.24, attributed to reduced cash receipts from product sales[9]. - The cash and cash equivalents at the end of the period decreased to $21.68 million from $85.99 million, a decline of about 74.7%[25]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 38,590[14]. - The largest shareholder, Rongjie Investment Holding Group Co., Ltd., holds 14.54% of shares, totaling 116,912,302 shares[15]. - The company has no preferred shareholders as of the reporting date[16]. Inventory and Expenses - The company’s inventory increased by 40.49% to ¥209,557,516.71, driven by product purchases by its U.S. subsidiary[9]. - The company’s financial expenses increased significantly, showing a decrease of 1242.54% to -¥11,406,672.37, influenced by currency exchange rate fluctuations[11]. - The company’s deferred income decreased by 92.80% to ¥9,447.96, reflecting the recognition of income during the reporting period[10]. - The company's inventory increased from ¥149,163,353.47 to ¥209,557,516.71, an increase of approximately 40.5%[18]. - Total operating costs decreased to $317.87 million from $358.50 million, a reduction of about 11.4%[21]. Investment Income - The company reported a significant increase in investment income of 1393.25%, amounting to ¥132,698,822.50, primarily due to the sale of equity in Zhongsheng Suoyuan[11]. - The company reported a significant increase in investment income to $132.70 million from $8.89 million, representing a growth of approximately 1,392.2%[22].